Bringing doctors together

or

A free, private network for verified physicians

Leading voices

Dr. Nishant Shah

Preventive Cardiology · Duke Hospital

View

Dr. Amit Khera

Preventive Cardiology · UT Southwestern

View

Dr. Martha Gulati

Preventive Cardiology · Houston Methodist

View

Dr. Pradeep Natarajan

Preventive Cardiology · MGH

View

Dr. Christopher Cannon

Preventive Cardiology · BWH

View

Dr. Nicholas Marston

Preventive Cardiology · BWH

View

Dr. Dorairaj Prabhakaran

General Cardiology

View

Dr. Pugazhendhi Vijayaraman

EP · Geisinger

View

Dr. Robert Schaller

EP · HUP

View

Dr. Trey Woods

General Cardiology · Emory Healthcare

View
  • Discover your community

  • Stay current

  • A profile that represents you

  • Find your people

About RoonPrivacyTerms

    Overview

    Angiotensinogen Reconsidered: Evolving Perspectives in Hypertension Research.

    Mar 19, 2026DOI: 10.1161/hypertensionaha.125.26091Journal ArticleAHA

    Written by: Mehmet KanbayMustafa GuldanLasin OzbekRama Al-ShiabLuke J Laffin

    Find these authors on Roon

    LL
    Dr. Luke Laffin
    Preventive Cardiology · Cleveland Clinic

    Summary

    Hypertension is the leading modifiable risk factor for cardiovascular disease, stroke, chronic kidney disease, and premature mortality. Although AGT (angiotensinogen) is a central component of the renin-angiotensin-aldosterone system, it was historically viewed primarily as a biochemical substrate rather than an active regulator of blood pressure and received less attention as a therapeutic target in hypertension compared with downstream renin-angiotensin-aldosterone system components such as angiotensin-converting enzyme and angiotensin II receptors. However, emerging evidence highlights its dynamic, tissue-specific role in blood pressure regulation and its responsiveness to metabolic, hormonal, and inflammatory stimuli. This narrative review examines the molecular biology, structure-function relationships, and regulatory mechanisms of AGT, including genetic variants such as M235T and -6G>A, which contribute to interindividual and population-level susceptibility to hypertension. We further explore AGT's pathogenic role in salt-sensitive hypertension, obesity-related inflammation, and renin-angiotensin-aldosterone system escape phenomena. Recent translational advances, including RNA-based therapeutics such as small interfering RNAs (zilebesiran) and antisense oligonucleotides (tonlamarsen), demonstrate promising blood pressure reductions and favorable safety profiles in clinical trials. AGT also shows potential as a biomarker for hypertensive nephropathy and treatment responsiveness. This review underscores the value of AGT as an upstream therapeutic target and diagnostic marker, offering new avenues for precision medicine and long-acting strategies in the management of both conventional and resistant hypertension while possibly addressing medication adherence-related obstacles.
    LLDr. Luke Laffin

    Dr. Luke Laffin

    Cardiology · Preventive Cardiology
    Cleveland Clinic
    luke